AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31819619
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT)
Trial: 26093812
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy plus radiotherapy (IC+RT)
Trial: 20528796
Drug: 500mL of
RxNorm normalized name: Reveos Select CPD with AS-5 Red Cell Preservative Solution For Collection Of 500ml Of Blood KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mL of 100% mandarin juice daily
Trial: 15924512
Drug: Water-based exercise
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based exercise and self-management program (10-week duration, conducted twice a week for one hour)
Trial: 8788291
Drug: High-lipase enteric-coated
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-lipase enteric-coated microsphere preparation
Trial: 8788291
Drug: Low-lipase enteric-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-lipase enteric-coated microsphere preparation
Trial: 6218815
Drug: 5% (w/v)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% (w/v) benzoyl peroxide gel
Trial: 6218815
Drug: 1.5% (w/v)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% (w/v) erythromycin lotion
Trial: 23225539
Drug: Amitriptyline (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (high-dose level)
Trial: 21858807
Drug: HPV-16/18 AS04-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 AS04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals)
Trial: 20048654
Drug: Single-injection ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection ultrasound-guided infraclavicular block
Trial: 20048654
Drug: Double-injection ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-injection ultrasound-guided infraclavicular block
Trial: 20048654
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly defined, but implied as the single-injection group)
Trial: 15906589
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine formulation A (21 mg/day)
Trial: 15906589
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine formulation B (21 mg/day)
Trial: 9861122
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg i.v. followed by infusion at a rate of 90 mg/15.5 h
Trial: 9861122
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg followed by infusion of 75 mg/15.5 h
Trial: 9861122
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg followed by infusion of 100 mg/15.5 h
Trial: 25727941
Drug: Corn silk
RxNorm normalized name: CORN SILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn silk aqueous extract (60, 130, 192.5 and 260 mg/kg body weight)
Trial: 17238221
Drug: Current drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current drug treatment
Trial: 17238221
Drug: Alternative hypothetical
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative hypothetical drug
Trial: 17238221
Drug: No preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preventive medication
Trial: 14667152
Drug: Melatonin (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (1.8 mg sustained release)
Trial: 14667152
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intermittent bright light, dark sunglasses, and regular early daytime dark/sleep period
Trial: 10612322
Drug: Statin drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin drug treatment
Trial: 6144522
Drug: Clorazepate 15
RxNorm normalized name: clorazepate 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate 15 mg nocte
Trial: 6144522
Drug: Lorazepam 1
RxNorm normalized name: lorazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1 mg t.d.s.
Trial: 18074761
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy alone (control)
Trial: 27484801
Drug: neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy plus trastuzumab, lapatinib or both
Trial: 26162993
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells (WJMSCs)
Trial: 23412022
Drug: Cosmetic slimming
RxNorm normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosmetic slimming treatment (twice a day for 4 weeks)
Trial: 20303209
Drug: Closed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed treatment with rigid maxillomandibular fixation
Trial: 15708387
Drug: Ivermectin high
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin high dose (800 microg/kg) given three-monthly
Trial: 15708387
Drug: Ivermectin standard
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin standard dose (150 microg/kg) given annually
Trial: 15708387
Drug: Ivermectin high
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin high dose (800 microg/kg) given annually
Trial: 12906959
Drug: Two simultaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two simultaneously consumed 400 microg OTFC doses
Trial: 12906959
Drug: One 800
RxNorm normalized name: metaxalone 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 800 microg OTFC dose
Trial: 10543484
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (HC), n = 14
Trial: 8912225
Drug: Cumulative dose-response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cumulative dose-response curve
Trial: 8912225
Drug: Noncumulative dose-response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Noncumulative dose-response curve
Trial: 1841573
Drug: Serologic studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serologic studies (antinuclear antibody test, fluorescent treponemal antibody absorption test)
Trial: 31187261
Drug: Iron picolinate
RxNorm normalized name: iron picolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron picolinate (2.5 mg 57Fe per serving, two servings)
Trial: 31187261
Drug: Iron sulfate
RxNorm normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron sulfate (2.5 mg 54Fe per serving, two servings)
Trial: 31187261
Drug: Relative bioavailability
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relative bioavailability of Fe picolinate versus Fe sulfate
Trial: 30378695
Drug: Alpinia officinarum
RxNorm normalized name: ALPINIA OFFICINARUM LEAF
DrugBank: Alpinia officinarum leaf (DB15789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpinia officinarum extract (300 mg daily for 3 months)
Trial: 26629352
Drug: Proteinuria <0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proteinuria <0.7 g/day after 12 months of treatment
Trial: 4041332
Drug: LA propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA propranolol 160 mg
Trial: 4041332
Drug: LA propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA propranolol 320 mg
Trial: 4041332
Drug: LA propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA propranolol 160 mg and 320 mg
Trial: 27974693
Drug: Nimotuzumab with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab with concurrent chemotherapy and radiotherapy
Trial: 26836793
Drug: Dabigatran (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (150 mg twice daily)
Trial: 19966341
Drug: Warfarin (dose-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (dose-adjusted to INR 2.0 to 3.0)
Trial: 10567779
Drug: Gemifloxacin (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin (320 mg, p.o., once daily)
Trial: 8584455
Drug: Spirulina fusiformis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina fusiformis (1 g/day for 12 months)
Trial: 25681068
Drug: Dalbavancin 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin 1000 mg intravenous (i.v.)
Trial: 25681068
Drug: Dalbavancin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin 1500 mg intravenous (i.v.)
Trial: 25681068
Drug: Placebo intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous (i.v.)
Trial: 21733508
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus combined hormonal oral contraceptive (OC)
Trial: 14609531
Drug: Ginger extract
RxNorm normalized name: ginger extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger extract (Zintona EC) 250 mg of Zingiberis Rhizoma per capsule, qid
Trial: 3963032
Drug: Buspirone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (all doses)
Trial: 22240397
Drug: Tri‐antigen combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri‐antigen combination of rApxIA, rApxIIA and rApxIIIA
Trial: 22240397
Drug: Hexa‐antigen vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexa‐antigen vaccine containing rApfA
Trial: 22240397
Drug: Immunization with
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunization with rApfA alone or in combination with other antigens
Trial: 20175977
Drug: tramadol/acetaminophen 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol/acetaminophen 37.5 mg/325 mg
Trial: 18771003
Drug: Azelnidipine 8
RxNorm normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine 8 mg
Trial: 12675275
Drug: Azelnidipine 16
RxNorm normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine 16 mg
Trial: 18771003
Drug: Azelnidipine 8
RxNorm normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine 8 mg, q.d. (multiple doses)
Trial: 12524662
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone replacement for 8 weeks
Trial: 12524662
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone replacement for 40 weeks
Trial: 10783995
Drug: Intravenous L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-arginine (500 mg/kg body weight/120 min)
Trial: 8115696
Drug: Naloxone 2
RxNorm normalized name: naloxone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 2 mg
Trial: 6835887
Drug: Hyoscine 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine 1.6 mg
Trial: 30688135
Drug: Pregabalin 10
RxNorm normalized name: pregabalin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 10 mg/kg/d
Trial: 30688135
Drug: Pregabalin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 2.5 mg/kg/d
Trial: 22047669
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy Competence Scale for Social Phobia (CTCS-SP)
Trial: 20578869
Drug: Chin cup
RxNorm normalized name: CHIN-UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chin cup with 600 g of force per side (Group 1, n = 20)
Trial: 20578869
Drug: Chin cup
RxNorm normalized name: CHIN-UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chin cup with 300 g of force per side (Group 2, n = 20)
Trial: 20578869
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Group 3, n = 10)
Trial: 15699762
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (3 g/day, n=36)
Trial: 15699762
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir (8 g/day, n=35)
Trial: 15699762
Drug: Deferred therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred therapy (n=12)
Trial: 11909906
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of daily living (ADL) scores
Trial: 29910030
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid 180 mg once daily added to ezetimibe 10 mg/day for 12 weeks
Trial: 29910030
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to ezetimibe 10 mg/day for 12 weeks
Trial: 22866693
Drug: Culturally accommodated
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally accommodated cognitive-behavioral treatment (A-CBT)
Trial: 22866693
Drug: Standard cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive-behavioral treatment (S-CBT)
Trial: 28303530
Drug: BTH1677 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTH1677 (4 mg/kg, weekly) + cetuximab (initial dose 400 mg/m2, subsequent doses 250 mg/m2, weekly) + carboplatin (6 mg/mL/min AUC, Q3W) + paclitaxel (200 mg/m2, Q3W)
Trial: 25601916
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g acetyl-l-carnitine for 12 weeks
Trial: 23020996
Drug: Long GnRH
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long GnRH agonist protocol (group I)
Trial: 23020996
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol (group II)
Trial: 20543747
Drug: CHO drink
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO drink (2:1 glucose-fructose blend; 1.5 g·min)
Trial: 20543747
Drug: Plain water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain water (WAT; 675 mL·h)
Trial: 9250837
Drug: Discolouration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discolouration of the teeth before treatment
Trial: 8039040
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of salbutamol (0.5 mg)
Trial: 8039040
Drug: Nebulization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of salbutamol (10 mg)
Trial: 8039040
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (i.v. and nebulization)
Trial: 23712109
Drug: Control (treatment-as-usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (treatment-as-usual wait list)
Trial: 6794081
Drug: Naloxone 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.8 mg
Trial: 18075400
Drug: Adenosine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (various doses)
Trial: 11498727
Drug: B. monniera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B. monniera (300 mg)
Trial: 7601299
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral sumatriptan
Trial: 1317294
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg oral aspirin plus 10 mg oral metoclopramide
Trial: 27090149
Drug: 8-week vocal
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week vocal music therapy treatment group
Trial: 21081251
Drug: Sildenafil 20mg
RxNorm normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 20mg thrice daily in addition to bosentan
Trial: 17469728
Drug: Rectal artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rectal artesunate 10 mg/kg/day for 3 days followed by oral mefloquine 25 mg/kg
Trial: 17469728
Drug: Rectal artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rectal artesunate 20 mg/kg/day for 3 days followed by oral mefloquine 25 mg/kg
Trial: 15207886
Drug: Rimostil (57.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimostil (57.2 mg total isoflavones)
Trial: 15207886
Drug: Promensil (82
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promensil (82 mg total isoflavones)
Trial: 11699249
Drug: Various herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various herbal therapies
Trial: 9828735
Drug: Oral vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vancomycin (15 mg/kg every 8 hours for 7 days)
Trial: 16764869
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives initiated at 10 mm follicle diameter
Trial: 16764869
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives initiated at 14 mm follicle diameter
Trial: 16764869
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives initiated at 18 mm follicle diameter
Trial: 11724652
Drug: Ultrasonically nebulized
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonically nebulized distilled water (UNDW) 8 ml
Trial: 11724652
Drug: Ultrasonically nebulized
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonically nebulized distilled water (UNDW) 16 ml
Trial: 16179403
Drug: N(G)-nitro-L-arginine methyl
RxNorm normalized name: methyl L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-nitro-L-arginine methyl ester (L-NAME)
Trial: 11724652
Drug: Ultrasonically nebulized
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonically nebulized distilled water (UNDW) after L-NAME
Trial: 9129015
Drug: Tumor-specific idiotype
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor-specific idiotype vaccine (tumor Ig protein coupled to keyhole limpet hemocyanin and emulsified in an immunologic adjuvant)
Trial: 9129015
Drug: Tumor-specific idiotype
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor-specific idiotype vaccine
Trial: 7895178
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human parathyroid hormone (PTH 1-38) infusion for 24 hours in 14 healthy females
Trial: 31237948
Drug: Antibiotic exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic exposure (from 14 days before to 7 days after vaccination)
Trial: 31237948
Drug: Nonexposed to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonexposed to antibiotics
Trial: 28739134
Drug: Dextromethorphan (DXM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DXM) 0.8 mg/kg
Trial: 26697137
Drug: n‐3 long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 long chain polyunsaturated fatty acids (n‐3 LC‐PUFA) enriched enteral formula (98 mg/d eicosapentaenoic acid and 46 mg/d docosahexaenoic acid)
Trial: 20801941
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OM) 20 mg/day for 3 weeks, uptitrated to OM 40 mg/day, OM/HCTZ 40/12.5 mg/day, and OM/HCTZ 40/25 mg/day
Trial: 15845566
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m(2) on days 1 and 8 plus docetaxel 50 mg/m(2) on day 8